Prostate Cancer

Latest News


Latest Videos


CME Content


More News

The next-generation androgen receptor apalutamide, in combination with androgen deprivation therapy, demonstrated a 25% reduction in the risk of death compared with placebo/ADT in patients with nonmetastatic castration-resistant prostate cancer in the phase III SPARTAN trial.

Conflicting guidelines on prostate-specific antigen testing have affected trends on disease presentation and, potentially, the treatment outcomes for many men with this disease. New agents and powerful new imaging tools have added yet more complexity to the decision process. Therefore, more investigation and cooperation on multiple levels is needed to define appropriate standards of care.